Patients using GLP-1 therapies often experience a steady weight loss of up to 3 pounds per week
Avoid self-prescribing, as it can lead to poor results or unnecessary risks.
This phenomenon might be noticeable in the first few weeks of treatment or after dose increases, though this mechanism has not been specifically studied in GLP-1 clinical trials
For patients taking warfarin or other coumarin derivatives, more frequent monitoring of INR (International Normalised Ratio) is recommended when starting semaglutide treatment, as weight loss and dietary changes can affect drug metabolism and effectiveness
Low GSH, neutrophil infiltration, myeloperoxidase activity and inflammation increase oxidative stress overwhelming the antioxidant defense, and hypochlorous acid mediated GSH oxidation and its attachment to proteins contribute to further GSH deficiency (114)
Ive discussed some of these in earlier blog posts about gastroparesis and vision problems, like NAION